Published in Blood Weekly, June 5th, 2003
First quarter loss per share narrowed to $.01, a $.04 per share improvement over the first quarter of 2002. The company generated a positive EBITDA in the first quarter.
First quarter sales growth of 40.5% was due to a combination of strong growth in the company's core concentrate product lines and to the expansion of ancillary product sales. The company realized substantial growth from its Dri-Sate Dry Acid Concentrate product line with sales up 45% from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.